Autism – Drug Pipeline Analysis and Market Forecasts to 2016

Tuesday, February 23, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Autism – Drug Pipeline Analysis and Market Forecasts to 2016 This report provides key data information and analysis on the autism market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009 and forecasts forward
seven years to 2016. The research also includes market characterization opportunities the unmet needs competitive assessments the product profiles of major marketed products and promising drugs in the pipeline an overview on discontinued projects implications
for future market competition and the key players of the autism market. ( ) The Autism Therapeutics Market is Forecast to Show Increased Growth until 2016 It has estimated the global autism therapeutics market to be valued at $331m in 2009. It is expected to grow to $649m with a compound annual growth rate (CAGR) of 11.5% by 2016. This growth is primarily attributed to the high increase in prevalence and also the fast increase in public awareness about the disease. Globally the US remains the largest market for autism therapeutics and was valued at $189m in 2009. It is forecast to grow at a CAGR of 12.9% over the next seven years to reach $442m by 2016. Weak and Steady Increase in Disease Population to Boost the Present Market The prevalence rate for autism globally was identified at 0.6% and this accounted for approximately 4.3 million people. Between 2009 and 2015 it is expected to increase from 4.3 million to seven million. The key factor attributed to this is the high incidence rate in new born in all parts of the world. Autism is highly prevalent in people aged one to eight. A significant increase in autism incidence has occurred over the past 10 years especially in the new born population. From the above data it is clear that the number of autism (ASD) patients seeking treatment in the next five to 10 years would result in an increased usage of therapeutics drugs which in turn would drive the ASD therapeutics market. Only Two Products Approved For Treatment The global autism market is dependent on only two FDA approved drugs. Most patients are prescribed anti-depressant or anti-psychotic drugs to treat the symptoms related to autism. The patent expiry of marketed products such as Risperdal by 2008 allowed the entry of generic products at cheaper prices reducing the market growth as well as the market size. High Unmet Need in Terms of Safety Profile The unmet need for autism therapeutics is estimated to be approximately $166m. Currently there is a significant market group that is likely to switch to new products with better efficacy and in particular safety. As presented above this unmet need is approximately 55% of the total market which is valued at $331m. Therefore the unmet need within the Autistic Disorder therapeutics market was estimated to be at least $182m in 2009. Based on our forecasts this need is likely to grow to approximately $357m by 2016. There is unmet need in terms of safety for which technologically innovative products will be required for value capture. The pipeline has limited emerging therapies that are likely to increase the growth of the present market. To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Blog: Follow us on twitter:

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store